Association between FOXP3 promoter polymorphisms and cancer risk: A meta‑analysis

Jiang,Ling‑Ling; Ruan,Li-Wei

doi:10.3892/ol.2014.2585

Association between FOXP3 promoter polymorphisms and cancer risk: A meta‑analysis

Authors:
- Ling‑Ling Jiang
- Li-Wei Ruan
View Affiliations

Affiliations: Department of Neurology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215002, P.R. China, Department of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: October 2, 2014 https://doi.org/10.3892/ol.2014.2585
Pages: 2795-2799

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidemiological studies have been conducted to investigate the association between the FOXP3 promoter polymorphisms, rs3761549 and rs3761548, and the risk of cancer. However, the results from these studies have been controversial. In order to obtain a more precise conclusion of this association, the present meta‑analysis was performed. The odds ratio (OR) and 95% confidence interval (95% CI) values were used to assess any correlations between the data. Overall, the rs3761549 (C>T) and rs3761548 (C>A) polymorphisms of the FOXP3 gene were not associated with the cancer risk in an Asian population. In the subgroup analyses based on cancer type, no significant associations were identified between these two polymorphisms and breast cancer. However, the results altered when the analyses were restricted to hepatocellular carcinoma (HCC) and non‑small cell lung cancer (NSCLC) (for rs3761549: TT+CT vs. CC OR, 0.52, 95% CI, 0.38‑0.72; TC vs. CC OR, 0.25, 95% CI, 0.16‑0.39; T vs. C OR, 0.76, 95% CI, 0.59‑0.97. For rs3761548: AA vs. AC+CC OR, 3.20, 95% CI 1.76‑5.81; AA+AC vs. CC OR, 2.56, 95% CI, 1.75‑3.76; AA vs. CC OR, 4.41, 95% CI, 2.36‑8.25; AC vs. CC OR, 2.15, 95% CI, 1.42‑3.25; A vs. C OR, 2.32, 95% CI, 1.74‑3.10). The present meta‑analysis indicates that the FOXP3 rs3761549 (C>T) and rs3761548 (C>A) polymorphisms are not associated with the risk of breast cancer, but with the risk of HCC and NSCLC. Therefore, a study with a larger sample size is required to further evaluate this association.

View Figures

View References

1	Gao X, Huang M, Liu L, et al: Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations. PLoS One. 8:e551692013.
2	Ying H, Wang J and Gao X: CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects. Tumour Biol. 35:5895–5904. 2014.
3	Schneeberger A, Koszik F and Stingl G: Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol. 105(Suppl 1): S110–S116. 1995.
4	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003.
5	Roncador G, Garcia JF, Garcia JF, et al: FOXP3, a selective marker for a subset of adult T-cell leukemia/lymphoma. Leukemia. 19:2247–2253. 2005.
6	Wang L, Liu R, Li W, et al: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 16:336–346. 2009.
7	Zuo T, Liu R, Zhang H, et al: FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 117:3765–3773. 2007.
8	Bennett CL, Brunkow ME, Ramsdell F, et al: A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA→AAUGAA) leads to the IPEX syndrome. Immunogenetics. 53:435–439. 2001.
9	Gupta S, Joshi K, Wig JD and Arora SK: Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol. 46:792–797. 2007.
10	Karanikas V, Speletas M, Zamanakou M, et al: FOXP3 expression in human cancer cells. J Transl Med. 6:192008.
11	Katoh H, Zheng P and Liu Y: Signalling through FoxP3 as an X-linked tumor suppressor. Int J Biochem Cell Biol. 42:1784–1787. 2010.
12	Chen Y, Zhang H, Liao W, et al: FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 32:392013.
13	He YQ, Bo Q, Yong W, Qiu ZX, Li YL and Li WM: FoxP3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population. Gene. 531:422–425. 2013.
14	Jahan P, Ramachander VR, Maruthi G, Nalini S, Latha KP and Murthy TS: Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol. 35:3785–3791. 2014.
15	Raskin L, Rennert G and Gruber SB: FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genet Cytogenet. 190:40–42. 2009.
16	Zheng J, Deng J, Jiang L, et al: Heterozygous genetic variations of FOXP3 in Xp11.23 elevate breast cancer risk in Chinese population via skewed X-chromosome inactivation. Hum Mutat. 34:619–628. 2013.
17	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
18	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.
19	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986.
20	Zuo T, Wang L, Morrison C, et al: FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 129:1275–1286. 2007.
21	Liu R, Wang L, Chen G, et al: FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res. 69:2252–2259. 2009.
22	Li W, Wang L, Katoh H, et al: Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 71:2162–2171. 2011.
23	Katoh H, Qin ZS, Liu R, et al: FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell. 44:770–784. 2011.
24	Marson A, Kretschmer K, Frampton GM, et al: FoxP3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 445:931–935. 2007.